NextBio and Cancer Care Institute Form Strategic Partnership Focused on Clinical Use of Genomics

NextBio and Cancer Care Institute Form Strategic Partnership Focused on Clinical Use of Genomics

SANTA CLARA, Calif.--NextBio and Cancer Care Institute (CCI) announced today a strategic partnership aimed at furthering the adoption of genomics in the clinic. The collaboration will facilitate use of the NextBio platform to interpret genomic molecular data for oncology patients and streamline the complete workflow for use of molecular data in a clinical setting.

"Cancer Care Institute cares for a very diverse group of patients of many different races and ethnicities, so we often see findings and trends that are not captured in the literature," said Morteza Dowlatshahi, M.D., Medical Director of Cancer Care Institute. "NextBio Clinical provides a powerful, easy-to-use way to interpret our patients' genomic data to conduct research studies as well as identify optimal treatments. We look forward to integrating NextBio into our daily clinical workflow."

"The ability to positively impact the treatment for a patient by understanding their individual genome and identifying actionable variants by correlating the patient's data with thousands of similar patients is truly rewarding," said Alpana Verma-Alag, M.D., Head of Clinical Development at NextBio. "Using Big Data technologies, we can now meaningfully interpret the molecular data from a person in a short amount of time, which has phenomenal implications for translational research and patient care."

"Our partnerships with Cancer Care Institute and other clinical centers complement our long-time work with pharmaceutical and biotechnology companies and research centers," said Saeid Akhtari, Co-Founder, President, and Chief Executive Officer of NextBio. "It has always been NextBio's goal to serve the full spectrum of life sciences research, from the laboratory to translational research to the clinic, thus enabling the latest advancements in genomics and other –omics research to ultimately spread to patient benefits in a seamless manner."

About Cancer Care Institute

Cancer Care Institute is a comprehensive state of the art radiation cancer center located on two campuses in San Jose and Morgan Hill, California. This center integrates medical, surgical, and radiation oncology and creates a synergy of medicine and research of science. Cancer Care Institute is at the forefront of cancer treatments and is involved in various research protocols involving National Cancer Institute (NCI) and Radiation Therapy Oncology Group (RTOG) clinical trials.

Cancer Care Institute offers the most advanced technologies such as intensity modulated radiation therapy (IMRT), Image guided radiation therapy (IGRT), stereotactic radiosurgery (SRS), high dose rate Brachytherapy (HDR) and radioembolization for the treatment of various cancers ranging from prostate, breast, lung, brain, head and neck, liver, gynecologic, lymphatic and colo-rectal.

Cancer Care Institute believes in providing patients and physicians with increasingly advanced technology keeping them on the cutting edge of treatment research, and encouraging the dissemination and sharing of information. Cancer Care Institute continues to make strides in the war on cancer.

About NextBio

NextBio provides a state of the art scientific platform to aggregate and interpret large quantities of genomic and other life sciences data for research and clinical applications. NextBio's platform integrates data from multiple repositories and diverse technologies by means of a unique correlation engine, which pre-computes billions of significant connections between disparate public and proprietary sources of clinical and experimental data. In doing so, the platform enables a seamless interoperability from instrument readouts to data interpretation for translational research and discovery. Backed by highly scalable, Big Data technology capable of analyzing petabytes of data in real-time, NextBio's platform is delivered as a SaaS (Software as a Service) solution resulting in quick deployment and rapid return on investment.

Today, NextBio is used by researchers and clinicians in over 40 top commercial and academic institutions including the University of Southern California, Sanford-Burnham Medical Research Institute, Celgene, Eli Lilly, Genzyme, Johnson & Johnson, Merck, Regeneron, Scripps Research Institute, Stanford University, University of California at Berkeley Takeda and many others. To learn more about NextBio, please visit our website at http://www.nextbio.com.


Contacts


NextBio
Saeid Akhtari
President and CEO
[email protected]
or
Kureczka/Martin Associates
Joan Kureczka, 415-821-2413
Mobile: 415-690-0210
[email protected]

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.